share_log

EFFECT: Others

SEC ·  Aug 2 18:10

Summary by Futu AI

eFFECTOR Therapeutics, Inc. has achieved a significant milestone with the announcement of its Notice of Effectiveness from the United States Securities and Exchange Commission (SEC) on August 1, 2024. The notice indicates that the company's submission, filed under the number 333-262339, has been reviewed and accepted by the SEC. This development is a key step in the regulatory process, allowing eFFECTOR Therapeutics to proceed with its planned activities as outlined in the submission type POS AM.
eFFECTOR Therapeutics, Inc. has achieved a significant milestone with the announcement of its Notice of Effectiveness from the United States Securities and Exchange Commission (SEC) on August 1, 2024. The notice indicates that the company's submission, filed under the number 333-262339, has been reviewed and accepted by the SEC. This development is a key step in the regulatory process, allowing eFFECTOR Therapeutics to proceed with its planned activities as outlined in the submission type POS AM.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated